Clairity, Inc., a digital health innovator advancing AI-driven healthcare solutions, has received U.S. Food and Drug Administration (FDA) De Novo authorization for CLAIRITY BREAST, a novel, image-based prognostic platform designed to predict five-year breast cancer risk from a routine screening mammogram. With this authorization, Clairity is planning to launch among leading health systems through 2025 – propelling a new era of precision medicine in breast cancer.

Cancer cell movement during metastasis is a dynamic process regulated by several different signals. However, the way cells receive, process and respond to these signals has been extremely hard to detect, but is now made easier by a new visualisation tool.